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ABSTRACT
Thrombin-inhibitingDNAaptamershavealreadybeen
obtained through the systematic evolution of ligands
byexponentialenrichment(SELEX).However,SELEX
is a method that screens DNA aptamers that bind
to their target molecules, and it sometimes fails to
screen good inhibitors. Therefore, it is necessary to
develop a method of screening DNA aptamers based
on their inhibitory effects on the target molecules.
We developed a novel method of detecting aptamers
using an evolution-mimicking algorithm, and we
applied it to the search of new aptamers which inhibit
thrombin. First, we randomly designed and syn-
thesized ten 15mer oligonucleotides presumed to
form G-quartet structures, and then measured their
thrombin-inhibiting activities. The aptamers showing
highinhibitoryactivitywereselected,andweshuffled
and mutated those sequences in silico to generate
10 new sequences of next-generation aptamers.
After repeating the cycle five times, we successfully
obtained the same aptamers reported previously,
and they showed high inhibitory activity. In addition,
we added 8mer oligonucleotides to both the 50 and
the 30 end of the selected 15mer aptamers, and then
repeated the evolution in silico. After two cycles, we
were able to obtain aptamers with higher inhibitory
activity than that of the 15mer aptamers.
INTRODUCTION
Many aptamers which recognize various molecules have been
reported (1–4), and some of them showed very strong binding
in the nanomoles range, especially to protein. Some aptamers
withhighenzyme-bindingactivityalsoshowedhighinhibitory
activity, and can therefore be used as pharmaceuticals.
Aptamers are usually screened by systematic evolution of
ligands by exponential enrichment (SELEX) (5), but this type
of selection is based on binding activity, whereas the aptamer
showing the strongest binding activity is not always the best
enzyme inhibitor. The aptamer might bind to the part of
the enzyme which does not affect its activity, and therefore
the aptamer as inhibitor is ideally screened according to its
inhibitory activity.
Nevertheless, huge numbers of aptamers require screening,
and there is no method of assaying the inhibitory activities of
many aptamers simultaneously, which means that assays have
to be carried out one by one. A method of limiting the number
of aptamers to be assayed is necessary, and this could be
achieved by using an evolution-mimicking method, such as
a genetic algorithm (6).
We have already reported the screening of a trypsin-
inhibiting hexapeptide using a genetic algorithm (GA) (7).
In that case, 24 peptides consisting of six amino acids were
synthesized, and the inhibitory effect of each aptamer on tryp-
sin was assayed. The peptides showing high inhibitory activity
were selected and their sequences were ampliﬁed, crossed-
over and mutated using GA. After the GA operations were
performed, a new set of 24-peptide sequences was obtained
(the second generation) and the process was repeated. Con-
sequently, we successfully obtained a hexapeptide that effect-
ively inhibits trypsin activity. It was thus ascertained that an
evolution-mimicking algorithm (EMA) such as GA is useful
for searching functional peptide sequences effectively. We
have also reported the screening of a 15mer peptide which
has a high tendency to form an a helix, using GA (8). EMA
methods such as GA enable us to screen aptamers according to
characteristics other than target afﬁnity, such as inhibitory
activity and structural properties, by restricting the number
aptamers to be assayed.
In this study, we chose the DNA aptamer that binds to
thrombin as the model in applying EMA, since this 15mer
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doi:10.1093/nar/gni108aptamer forming a G-quartet for thrombin has already been
screened by SELEX and has shown thrombin-inhibiting
activity (9). This aptamer is one of the most well known;
its structure has already been determined (10–12) and the
effect of its loop sequence on the G-quartet structure has
been investigated (13). Extensive work to determine the
binding site has already been carried out, and the binding
site has been determined (14 17). Additionally, the applica-
tion of this thrombin-inhibiting aptamer as a drug has been
investigated, such as in the inhibition of clot formation in vivo
(18–21), and its stability in vitro (22) and in vivo (18) has been
determined.
Moreover, Macaya et al. (23) have synthesized longer
thrombin-inhibiting aptamers, which are essentially a 15mer
thrombin-inhibiting aptamer bearing a duplex of different
lengths at the 50 and 30 ends that forms the G-quartet structure,
and have investigated the thrombin-inhibiting activity of such
aptamers. The binding site of the 15mer thrombin-inhibiting
aptamer is positively charged, so that the aptamer bearing the
longer duplex was expected to show higher inhibitory activity,
since it would bind to the thrombin more strongly because of
the increased negative charge of the longer duplex. However,
Macaya et al. have found no clear correlation between the
inhibitory activity and the length of the aptamer duplex.
We presumed that the 3D position of the duplex relative to
the G-quartet structure might play an important role in the
binding of the aptamer to thrombin, and that there might
be an optimal direction of the duplex reaching out from the
G-quartet part. It is difﬁcult to predict the direction of the
duplex, but its sequence can be optimized using EMA. In
this case, the G-quartet structure is indispensable for the
inhibitory activity of the aptamer, and therefore the G-base
formation should remain intact, without mutation. However,
it is difﬁcult to introduce crossovers of the sequence through
GA while maintaining the G bases intact; hence we developed
a new algorithm to shufﬂe the sequence of the loop part of the
G-quartet structure among multiple parent aptamer sequences.
This sequence shufﬂing might mix up the aptamer sequences
more effectively than GA crossover, and it might result in an
increase of the diversity of aptamer sequences, which would
enable us to avoid local minima of the inhibitory activity of
the aptamers.
Using the thrombin-inhibiting aptamer as a model, we
investigated the effectiveness of applying EMA to the screen-
ing of aptamers as inhibitors. Some of the outcome of this
study were presented at the Third International Symposium
on Nucleic Acids Chemistry held at Sapporo, Japan in 2003
and it had already been published as an abstract (24).
MATERIALS AND METHODS
Materials
Bovine thrombin was purchased from Fisher Scientiﬁc Japan,
Ltd (Tokyo, Japan) and human thrombin was purchased
from Sigma (Missouri, USA). Imidazole buffer was purchased
from Fisher Scientiﬁc Japan, Ltd (Tokyo, Japan) and human
plasma was purchased from DADE Behring, Inc. (Liederbach,
Germany). All oligonucleotides were obtained from Sawady
Technology Corporation (Wako, Japan).
Evolution process using EMA
In the case of the 15mer DNA oligonucleotides, a set of ten
15mer DNA sequences with the form GGNNGGNNNGG-
NNGG (N ¼ A, G, C, T) (Figure 1A) was randomly generated
by a computer and synthesized. The scheme of evolution
in silico of these oligonucleotides using the EMA is illustrated
in Figure 2. The inhibitory effect of each oligonucleotide on
ﬁbrin clot formation was measured, and the 10 oligonuc-
leotides were ranked according to their thrombin times. The
top ﬁve oligonucleotides showing extended thrombin times
for clot formation were chosen, and the sequences of those
oligonucleotides were shufﬂed by a computer to generate a
new set of 10 sequences for the next generation. The three
loops attached to the presumed G-quartet structure were
divided into three blocks (Figure 2) and the 2- or 3-base
sequences in each block were shufﬂed within the same block
among the ﬁve oligonucleotide sequences. The appearance
rate of each block sequence was changed depending on the
rank of the oligonucleotide from which it was originated. After
Figure 1. Scheme of the DNA oligonucleotides and the presumed form of the G-quartet structure. (A) 15mer oligonucleotide. (B) 31mer DNA oligonucleotide.
N ¼ A, G, C, T.
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process, one base mutation per sequence was introduced
with variations in occurrence. The 10 new oligonucleotide
sequences for the next generation were then determined,
and they were synthesized for the next clot-inhibition assay.
By repeating this cycle, the oligonucleotide showing the
highest inhibitory effect on clot formation was found.
In the case of the  31mer DNA oligonucleotides, a set of
ten 31mer DNA sequences with the form GGTTGGTGTGGT-
TGG (N ¼ A,G, C,T)was randomly generated by acomputer
and synthesized.
Clot-inhibition assay
In order to determine the inhibitory effect of the oligonucleo-
tides on thrombin, a clot-inhibition assay was carried out. The
thrombin time was measured in order to evaluate clot inhibi-
tion. Fifty microlitres of imidazole buffer containing 30 mMo f
each oligonucleotide were added to 100 ml of human plasma
and incubated for 2 min at 37 C. Fifty microlitres of imidazole
buffer containing 25 NIH units of thrombin were then added to
the solution, and the thrombin time was measured.
Binding assay
The dissociation constant, Kd, was measured and calculated
using a Biacore 3000 (Biacore International AB, Neuchatel,
Switzerland).
RESULTS
Identification of the best 15mer oligonucleotide
using EMA
We ﬁrst synthesized a set of ten 15mer DNA oligonucleotides
bearing the sequence form of GGNNGGNNNGGNNGG
(N ¼ A, G, C, T), which is presumed to be in the form of
the G-quartet (Figure 1A), and measured the clot-inhibition
activity of each of the 10 oligonucleotides. We ranked the
10 oligonucleotides, and chose 5 of them to generate the
sequences of the next 10 oligonucleotides, using EMA.
The scheme of the evolution in silico of these oligonucleotides
using this algorithm is illustrated in Figure 2. In order to
evaluate the clot-inhibition activity, the extended thrombin
times to the thrombin time of a solution without any oligo-
nucleotide were calculated and compared. The cycle of
oligonucleotide synthesis, clot-inhibition assay and evolution
of the oligonucleotide sequences in silico using the EMA was
repeated seven times, with one cycle corresponding to one
generation when we assume this process to be the in silico
evolution of the thrombin-inhibiting oligonucleotides.
The extended thrombin time for each oligonucleotide in
each generation is shown in Figure 3, and each value is the
average of three measurement values. The thrombin time of
the negative control was 19.1 s. The ﬁrst-generation oligonuc-
leotides were randomly designed, leaving intact the G-quartet
structure, and they showed a slight extension of the thrombin
time. Those oligonucleotides were ranked according to their
inhibitory activity, and the top ﬁve oligonucleotide sequences
were selected for the production of the 10 next-generation
oligonucleotide sequences, using EMA. The sequences of
three different loops presumed to constitute G-quartet struc-
tures were divided into three blocks (Figure 1A), and
the sequences in each block were shufﬂed among the ﬁve
sequences selected (Figure 2). The appearance rate of the
sequences at each block was changed depending on the rank-
ing of the oligonucleotides, and the rank 1:rank 2:rank 3:
rank 4:rank 5 ratio was 5:4:3:2:1 in the 1st generation,
2:2:1:1:1 in the 2nd and 3rd generations, and was 1:1:1:1:1
from the 4th to 7th generations. These appearance rates were
changed depending on the extension of the thrombin time and
the homology of the oligonucleotide sequences showing high
thrombin-inhibition activity.
After 10 new oligonucleotide sequences were generated
through the shufﬂing of the sequences in each of the three
blocks, a mutation was introduced. We changed one base of
the oligonucleotide sequence (leaving the region forming the
G-quartet intact) to one of the other three bases. The rate of
introduction of the mutation was changed thus: one base muta-
tionpertwo oligonucleotides fromthe 1sttothe3rdgeneration
and one base mutation per one oligonucleotide after the
4th generation. Ten of the sequences generated through the
shufﬂing and mutation process were used as the 10 oligonuc-
leotide sequences for the next generation.
The average extended thrombin time progressively
increased until the 6th generation, and then decreased
(Figure 3B). The oligonucleotide showing the highest clot-
inhibition activity was obtained at the 5th generation, and
the sequence, GGTTGGTGTGGTTGG, was the same as that
of our model. The sequences of the top 10 oligonucleotides
Figure 2. Scheme of the EMA applied to the 15mer oligonucleotides.
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Table 1, and their corresponding extended thrombin times
are also shown. Each oligonucleotide was designated X-Y,
where X is the number of the generation and Y is the iden-
tiﬁcation number of the sequence. The best oligonucleotide,
which was identical to the one reported by Bock et al. (9), had
an extended thrombin time of 65.2 s and a total time of 84.3 s,
which was outstandingly high compared to the performance
of the other oligonucleotides. In order to further improve this
inhibitory effect, we next attempted to ﬁnd longer oligo-
nucleotides, following the suggestion in the report by Macaya
et al. (23).
Identification of the best 31mer oligonucleotide
using EMA
We designed a 31mer oligonucleotide library with the
sequence 50-CACTGNNNGGTTGGTGTGGTTGGNNNGA-
GTG-30, by adding 8mer oligonucleotides to both the 50 and
the 30 ends of the prototype thrombin-inhibiting aptamer, as
shown in Figure 1B. The ﬁve-base regions at the 50 and 30 ends
were designed to form a duplex, and the two loops composed
of the three bases connecting the duplex at the 50 and 30 ends to
the G-quartet structure of the prototype thrombin-inhibiting
aptamer were named Block 4 and Block 5, respectively.
We generated ten 31mer oligonucleotide sequences by
randomizing both Block 4 and Block 5, and evolved those
sequences in the same manner as in the case of the 15mer
oligonucleotide. The appearance rate of the sequences for each
block was changed as in the case of the 15mer oligonucleotide,
and the rank 1:rank 2:rank 3:rank 4:rank 5 ratio was 1:1:1:1:1
in all generations. A mutation of one base per one oligonuc-
leotide was introduced after the sequence shufﬂing in each
generation, and that mutation rate was not changed through-
out the search. The extended thrombin times caused by the
oligonucleotides are shown in Figure 4, and each value is the
average of three measurement values. The thrombin time
without the addition of any oligonucleotide was 19.1 s this
time as well. The average of the extended thrombin times did
not increase dramatically, but the oligonucleotides showing
longer thrombin times than the prototype thrombin-inhibiting
aptamer were obtained already in the 2nd and 4th generation.
The sequences of the top ﬁve oligonucleotides are shown in
Table 2. Each oligonucleotide was designated LX-Y, where
X is the number of the generation and Y is the identiﬁcation
number of the sequence.
The binding properties of the selected oligonucleotides
and a study of their mutations
An oligonucleotide which appeared in the 2nd generation,
L2-3, and one which appeared in the 4th generation, L4-2,
had thrombin times of 127 and 106.9 s, respectively, which
represents a great improvement in thrombin-inhibition activity
compared to that of the prototype 15mer thrombin-inhibiting
aptamer, which had a thrombin time of 80.8 s. We measured
the Kd value of both oligonucleotides; L2-3 showed 3.43 ·
10
 8 M and L4-2 showed 2.89 · 10
 8 M. Both of the selected
oligonucleotides showed greater Kd values than the prototype
15mer aptamer (which had a Kd value of 1.87 · 10
 8 M)
despite having higher inhibitory activities than the prototype
15mer aptamer. This result supports the hypothesis that the
screening of oligonucleotides according to their inhibitory
activity using EMA is more efﬁcient than afﬁnity selection,
if the aim is to obtain a good inhibitor.
Both L2-3 and L4-2 have the GTA sequence at Block 4 and
GGC or GGG, and so we made 12 sets of 1- or 2-base mutated
Table 1. The 15mer oligonucleotides showing high inhibition
Oligonucleotide Sequence Extended
thrombin time (s)
5-9 GG TT GG TGT GG TT GG 62.6
6-2 GG TT GG GAT GG TG GG 36.2
6-7 GG TT GG GGC GG TA GG 36.1
7-1 GG TT GG GGC GG CT GG 32.6
5-4 GG TT GG GGT GG TT GG 31.4
6-1 GG TT GG TTG GG TT GG 29.9
6-10 GG TT GG AGT GG TT GG 19.8
6-6 GG TT GG GCT GG TT GG 18.9
4-10 GG TT GG GTC GG TT GG 18.7
6-9 GG TT GG TCT GG TT GG 17.7
Figure 3. The extended thrombin time of the 15mer oligonucleotides in seven generations of EMA evolution. (A) The results for all oligonucleotides in the seven
generations.(B)Theaverageoftheextendedtimesforeachgeneration.Thethrombintimewasmeasuredbyadding50mlofimidazolebuffercontaining25NIHunits
of thrombin to 150 ml of imidazole buffer containing 30 mM of each oligonucleotide and 100 ml of human plasma and incubating at 37 C.
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results are shown in Table 3; interestingly, seven oligo-
nucleotides showed higher inhibitory activity than the proto-
type thrombin-inhibiting aptamer, but did not exceed that
of L2-3. More interestingly, ﬁve oligonucleotides showed
much lower inhibitory activity than the prototype thrombin
aptamer, which means that the sequences of these loops
critically inﬂuence the capacity of the oligonucleotides to
inhibit thrombin.
The measurements mentioned above were all performed
using bovine thrombin, and we measured the inhibitory effect
on human thrombin of L2-3, L4-2 and other oligonucleotides
showing high inhibitory effects on bovine thrombin. The
values were almost the same, and no signiﬁcant difference
was observed.
DISCUSSION
This is the ﬁrst report of a screening of oligonucleotides
according to their enzyme-inhibition function. This screening
was achieved by the use of EMA; otherwise it is very difﬁcult
to search or screen oligonucleotides according to their func-
tion, since there is no method of selecting functional oligo-
nucleotides simultaneously, except according to the binding.
If the aim is to screen oligonucleotides according to their
inhibitory properties, the inhibitory effect on the target
enzyme of each oligonucleotide must be measured one by
one. On the other hand, it is impossible to measure the inhib-
itory activities of all oligonucleotides in a library, and so the
number of oligonucleotides to be measured must be somehow
limited. For that purpose, EMA methods such as GA are very
Figure 4. The extended thrombin times of the 31mer oligonucleotides in five generations of EMA evolution. (A) The results for all oligonucleotides in the five
generations.(B)Theaverageoftheextendedtimesforeachgeneration.Thethrombintimewasmeasuredbyadding50mlofimidazolebuffercontaining25NIHunits
of thrombin to 150 ml of imidazole buffer containing 30 mM of each oligonucleotide and 100 ml of human plasma and incubating at 37 C.
Table 2. Top 31mer oligonucleotides showing high inhibition
Oligonucleotide Sequence Extended thrombin time (s)
Prototype GG TT GG TGT GG TT GG 61.7
L2-3 CACTG GTA GG TT GG TGT GG TT GG GGC CAGTG 108
L4-2 CACTG GTA GG TT GG TGT GG TT GG GGG CAGTG 87.8
L2-2 CACTG GCG GG TT GG TGT GG TT GG CGC CAGTG 68.5
L1-4 CACTG TAA GG TT GG TGT GG TT GG GTA CAGTG 58.6
L1-9 CACTG GCG GG TT GG TGT GG TT GG CTA CAGTG 53.8
Table 3. 31mer mutant oligonucleotides showing high inhibition
Oligonucleotide Sequence Extended thrombin time (s)
L6-4 CACTG GTA GG TT GG TGT GG TT GG AGC CAGTG 90.9
L6-7 CACTG CTA GG TT GG TGT GG TT GG GGG CAGTG 89.6
L6-1 CACTG GTA GG TT GG TGT GG TT GG ATC CAGTG 87.8
L6-11 CACTG GGA GG TT GG TGT GG TT GG GGC CAGTG 79.6
L6-6 CACTG GCG GG TT GG TGT GG TT GG GAC CAGTG 76.1
L6-5 CACTG GTA GG TT GG TGT GG TT GG GTC CAGTG 69.3
L6-12 CACTG GCA GG TT GG TGT GG TT GG GGC CAGTG 63.9
Prototype GG TT GG TGT GG TT GG 62.4
L6-3 CACTG GAT GG TT GG TGT GG TT GG GGC CAGTG 47.8
L6-2 CACTG GTA GG TT GG TGT GG TT GG GCC CAGTG 25.8
L6-9 CACTG GGG GG TT GG TGT GG TT GG GGC CAGTG 25.0
L6-10 CACTG GTA GG TT GG TGT GG TT GG CGC CAGTG 20.0
L6-8 CACTG GCC GG TT GG TGT GG TT GG GGC CAGTG 19.0
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trypsin-inhibiting hexapeptide and a 15mer peptide forming
an a helix by GA (7,8).
First, we tried to screen the 15mer oligonucleotides and
designed a library of sequences presumably forming the
G-quartet, using the thrombin-inhibiting aptamer screened
by Bock et al. (9) as a model. After the ﬁve cycles of EMA
evolution, we successfully obtained the oligonucleotide bear-
ing the samesequenceas the thrombin-inhibiting aptamer.The
designed library contained 4
7 (16384) sequence variations,
and the prototype thrombin-inhibiting aptamer was obtained
in the 5th generation. Fifty oligonucleotides were synthesized
and screened before the aptamer was found, so that 0.3% of
the total variations of the library was searched. We can say
that this screening method using EMA is effective, and the
usefulness of EMA was demonstrated in our screening of
oligonucleotide enzyme inhibitors. After the 5th generation,
the activity decreased since we removed the sequence that had
appeared at the evolution stage.
Considering the relation between sequence homology and
inhibitory effect shown in Figure 3 and Table 1, the TT
sequence at both Loop 1 and Loop 3 is important for the
inhibitory activity, and even a single mutation in the TGT
sequence at Loop 2 causes a serious decrease in inhibitory
effect. Therefore, the sequence dependency of thrombin
inhibition seems to be very exclusive, and the search for a
speciﬁc oligonucleotide insuch acase would berather difﬁcult
to undertake. We have already reported the search for a
trypsin-inhibiting hexapeptide (7); its inhibitory effect was
found to have broad sequence dependence. In that case, we
used a genetic algorithm, and a mild mutation was enough to
enable the identiﬁcation of that hexapeptide whose inhibitory
effect had broad sequence dependence, but it would be difﬁ-
cult to search through a sequence space bearing very sharp
peaks with that method, as in the case of this thrombin-
inhibiting aptamer.
Based on the results reported by Bock et al.(9), we expected
that the oligonucleotide we were looking for had a narrow
sequence dependence. We developed an algorithm of shufﬂing
the sequences of the loop part of the DNA among several
oligonucleotides while keeping the G-quartet structure intact,
and this also resulted in an improvement of the crossover rate,
and we succeeded in pinpointing the oligonucleotide identical
to the prototype thrombin-inhibiting aptamer. The appearance
rate of each sequence was changed in each generation depend-
ing on the inhibitory effect of the oligonucleotide. From the
1st to the 3rd generation, the appearance rates of the sequences
in each block of the highly ranked oligonucleotides were
raised in order to accelerate the search for the oligonucleotide
having a sequence similar to the oligonucleotide showing
the highest inhibition at the previous generation, but from
4th generation onward, the appearance rates of the sequences
at each block were equalized, in order to search through oligo-
nucleotides with various sequences and to avoid missing
oligonucleotides with potential inhibitory activity.
In the search of the 31mer oligonucleotides, most of the
aptamers showed lower inhibitory activity than the prototype
15mer aptamer. This means that the double helix connected
to the G-quartet structuremight be an obstacle to the inhibitory
action of the oligonucleotide in many cases. However, 3 out
of 50 oligonucleotides showed higher inhibitory activity;
therefore, it is reasonable to assume that there are rare
cases in which the double helix connected to the G-quartet
actually boosts the inhibitory activity. Our screening using
EMA did not fail to pick up those rare cases, which also
prove that this is an effective method of screening oligonuc-
leotides as inhibitors.
Tasset et al. (25) have reported a 29mer aptamer which
binds to a thrombin site different from that bound by the
15mer prototype thrombin-inhibiting aptamer, but it also
has a G-quartet structure and a duplex part. As such, it would
have been possible for the 29mer aptamer to appear in our
screening process, but it did not appear. This 29mer DNA
aptamer binds more strongly to thrombin than the prototype
15mer thrombin-inhibiting aptamer, but has lower inhibitory
activity. The fact that it failed to appear in our screening might
be due to the fact that we screened the oligonucleotides
according to their inhibitory activities.
In this study, we used an EMA screening method in search-
ing through oligonucleotides according to their enzyme-
inhibiting function not to their afﬁnity. We emphasize that
the essential architecture of the oligonucleotides was con-
served throughout the procedure in this work, and this archi-
tecture was derived from information obtained from SELEX,
so that our method described here is essentially a post-SELEX
optimization procedure. As a procedure, this has a signiﬁcant
potential since it can be applied to the screening of oligonuc-
leotides according to any other function than afﬁnity.
Aptamers are currently drawing attention as molecular
recognition elements, and their application to afﬁnity chroma-
tography (26), biosensing (27,28) and biosensors (29,30) is
now of great interest. Selectivity is one of the most important
properties of the molecular recognition element when con-
sidering practical application, and a screening method using
EMA would be effective in improving the selectivity of apta-
mers. This method has the potential for vast applications in
many ﬁelds, and a combination with SELEX or high through-
put screening methods such as microarrays will in turn
generate more applications.
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